Physician profile
Michael Hunter
NPI 1538801840
$1,264.90
in general payments reported to CMS, 2019-2025
14 companies · $956 in 2025
The $956 reported for 2025 was more than what 84% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.51 · 2023: $138 · 2024: $130 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $384.97 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Alnylam Pharmaceuticals INC. | $245.48 | 2024-2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $243.59 | 2022-2025 | Farxiga, Wainua, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $71.41 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $48.45 | 2023 | Eliquis |
| United Therapeutics Corporation | $46.76 | 2025 | Orenitram, Remodulin, Tyvaso |
| Janssen Pharmaceuticals, INC | $40.57 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.67 | 2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $28.31 | 2023 | Assure Wcd |
| Gilead Sciences, INC. | $27.72 | 2023 | |
| Melinta Therapeutics, LLC | $26.15 | 2024 | Orbactiv, Kimyrsa |
| Novo Nordisk INC | $24.21 | 2025 | Rybelsus, Ozempic |
| Scpharmaceuticals INC. | $21.49 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $16.12 | 2023 | Caldolor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.